As we reach the middle of March, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly moves and YTD moves
Highlights for the week of 3/7 - 3/11
Biggest positive move
$CNTB +59.2%
Biggest negative move
$NKTR -47.3% Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma.
Additional big moves
$EIGR +55.3% Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study
$JAGX +53.9% Investor webcast on 3/14/22 from fourth quarter financials
$AVEO +49.7% Fourth quarter financial results
$HGEN +36.9%
$MRNS +28.4% Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder.
$APLS +22.2% Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA).
$PLX +20.7% Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of the BRIGHT Phase III Clinical Trial Evaluating PRX-102 for the Treatment of Fabry Disease.
$SYGGF +17.1% Synairgen Provides Update on ACTIV-2 Trial (halting enrollment)
$IFRX +12.3% InflaRx Receives Corrected Advice Letter from FDA Related to Phase III Program for Vilobelimab in Hidradenitis Suppurativa
$ANAB -11.9% ANAPTYSBIO REPORTS IMSIDOLIMAB ACORN PHASE 2 CLINICAL TRIAL DATA IN MODERATE-TO-SEVERE ACNE
$NUVL -22.5%
$NYMX -30.1% Nymox Announces $5 Million Registered Direct Offering.
Highlights for next week
Companies with commercial assets reporting Q4 '21 results next week:
$IMPL
Watch over the next few weeks for quarterly company reports including commercial sales
See our Big Movers post to learn about the upcoming March Big Movers/Movers to Watch (includes several PDUFAs or the month)
Comments